Related Experiment Video
Updated: Aug 12, 2025

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth
Marina Badenes1,2,3, Emma Burbridge1,4, Ioanna Oikonomidi1
1Instituto Gulbenkian de Ciência, Oeiras, Portugal.
Abstract:
The metalloprotease ADAM17 is a sheddase of key molecules, including TNF and epidermal growth factor receptor ligands. ADAM17 exists within an assemblage, the "sheddase complex," containing a rhomboid pseudoprotease (iRhom1 or iRhom2). iRhoms control multiple aspects of ADAM17 biology. The FERM domain-containing protein iTAP/Frmd8 is an iRhom-binding protein that prevents the precocious shunting of ADAM17 and iRhom2 to lysosomes and their consequent degradation. As pathophysiological role(s) of iTAP/Frmd8 have not been addressed, we characterized the impact of iTAP/Frmd8 loss on ADAM17-associated phenotypes in mice. We show that iTAP/Frmd8 KO mice exhibit defects in inflammatory and intestinal epithelial barrier repair functions, but not the collateral defects associated with global ADAM17 loss. Furthermore, we show that iTAP/Frmd8 regulates cancer cell growth in a cell-autonomous manner and by modulating the tumor microenvironment. Our work suggests that pharmacological intervention at the level of iTAP/Frmd8 may be beneficial to target ADAM17 activity in specific compartments during chronic inflammatory diseases or cancer, while avoiding the collateral impact on the vital functions associated with the widespread inhibition of ADAM17.
Insights
The FERM domain-containing protein iTAP/Frmd8 protects the metalloprotease ADAM17 from degradation. Loss of iTAP/Frmd8 impairs inflammatory repair and cancer growth, offering a targeted therapeutic approach for ADAM17-related diseases.
Area of Science:
- Molecular and Cellular Biology
- Biochemistry
- Immunology
Background:
- ADAM17 is a metalloprotease crucial for shedding TNF and EGF ligands, operating within a complex with iRhoms.
- iTAP/Frmd8, an iRhom-binding protein, stabilizes ADAM17 and iRhom2 by preventing lysosomal degradation.
Purpose of the Study:
- To investigate the pathophysiological roles of iTAP/Frmd8 by analyzing its impact on ADAM17-associated phenotypes in mice.
- To explore the potential of iTAP/Frmd8 as a therapeutic target for inflammatory diseases and cancer.
Main Methods:
- Generation and characterization of iTAP/Frmd8 knockout (KO) mice.
- Assessment of inflammatory and intestinal epithelial barrier repair functions in iTAP/Frmd8 KO mice.
- Evaluation of iTAP/Frmd8's role in cancer cell growth and the tumor microenvironment.
Main Results:
- iTAP/Frmd8 KO mice displayed defects in inflammatory and intestinal epithelial barrier repair, distinct from global ADAM17 loss phenotypes.
- iTAP/Frmd8 was found to regulate cancer cell proliferation both intrinsically and by influencing the tumor microenvironment.
- Loss of iTAP/Frmd8 did not replicate the collateral defects observed with global ADAM17 deficiency.
Conclusions:
- iTAP/Frmd8 plays a critical role in regulating ADAM17-mediated processes, particularly in inflammatory responses and epithelial repair.
- Targeting iTAP/Frmd8 offers a promising strategy for modulating ADAM17 activity in specific contexts like chronic inflammation and cancer.
- Pharmacological targeting of iTAP/Frmd8 could provide therapeutic benefits while mitigating the systemic side effects associated with broad ADAM17 inhibition.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of the Unfolded Protein Response
The JAK-STAT Signaling Pathway
Abnormal Proliferation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

